peptide elongation factor 2 has been researched along with Colorectal Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Branders, S; De Ridder, M; Defresne, F; Dieu, M; Dupont, P; Feron, O; Grandjean, M; Raes, M; Sermeus, A | 1 |
1 other study(ies) available for peptide elongation factor 2 and Colorectal Cancer
| Article | Year |
|---|---|
Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers.
Topics: Aged; Amino Acid Sequence; Animals; Antigens, Neoplasm; Autoantibodies; Biomarkers, Tumor; Cell Hypoxia; Cell Proliferation; Colorectal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Immunoassay; Male; Mice; Molecular Sequence Data; Peptide Elongation Factor 2; Phosphoproteins; Phosphorylation; Proteomics; Serologic Tests; Threonine | 2013 |